Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Novo Nordisk (NVO, Financials) shares fell nearly 4% after the company said CEO Lars Fruergaard Jrgensen will step down. A ...

At 72 weeks, Zepbound met the primary endpoint and ... and media to further detail the company's financial performance. Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Galloway Capital Partners, LLC and its affiliates (collectively, "Galloway") announced today that they are considering pursuing legal action against WW International, Inc. ("WW" or the "Company"), ...

Eli Lilly has raised its ... medicines Mounjaro for diabetes and Zepbound for obesity have led the charge, contributing $3.1 billion and $1.2 billion to Lilly's revenues for the period ...